ADMA Biologics (NASDAQ:ADMA – Get Free Report) and Passage Bio (NASDAQ:PASG – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Risk & Volatility
ADMA Biologics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for ADMA Biologics and Passage Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
| Passage Bio | 0 | 0 | 3 | 0 | 3.00 |
Valuation and Earnings
This table compares ADMA Biologics and Passage Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $330.24 million | 10.96 | -$28.24 million | ($0.02) | -781.00 |
| Passage Bio | N/A | N/A | -$102.06 million | ($1.53) | -0.38 |
ADMA Biologics has higher revenue and earnings than Passage Bio. ADMA Biologics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ADMA Biologics and Passage Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 10.53% | 38.79% | 17.35% |
| Passage Bio | N/A | -70.74% | -52.29% |
Insider & Institutional Ownership
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by company insiders. Comparatively, 4.3% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ADMA Biologics beats Passage Bio on 9 of the 13 factors compared between the two stocks.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
About Passage Bio
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
